Preventive effects of parecoxib sodium on postoperative shivering

Preventive effects of parecoxib sodium on postoperative shivering: a prospective, double blind, randomised clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002870

Enrollment

Unknown

Registered

2012-12-22

Start date

2011-12-12

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative shivering

Interventions

Group P:parecoxib sodium 40 mg

Group T:tramadol 2mg.kg-1

Group S:saline

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: ASA I-II, 30-60 yr patients,scheduled for elective abdominal surgical procedures under general anaesthesia were enrolled in the prospective randomised double- blind clinical trial.

Exclusion criteria

Exclusion criteria: Patients were excluded if with known allergy to any of the medications used,severe cardiovascular disease, kidney or liver dysfunction, petic ulceration, psychiatric disorders, muscle diseases, receiving intraoperative blood or blood products transfusion, history of convulsions or fever.

Design outcomes

Primary

Measure	Time frame
shivering;	—

Secondary

Measure	Time frame
pain intensity;temperature;	—

Countries

China

Contacts

Public ContactLi Xiouzhe

lijunfu020428@163.com+86 1381130420

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 10, 2026